Journal Publications

Academic peer reviewed journal articles which include Cancer Trials Ireland Members as co-authors

Peer Reviewed Journals

Study Number: Short Name

2020 Journal Publications

11-29: ICON 8B


Blagden, S. P., A. D. Cook, C. Poole, L. Howells, I. A. McNeish, A. Dean, J. W. Kim, D. M. O’Donnell, J. Hook, E. C. James, I. R. White, T. Perren, R. Lord, G. Dark, H. M. Earl, M. Hall, R. Kaplan, J. A. Ledermann & A. R. Clamp (2020) “Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial.” Lancet Oncol, 21, 969-977.
15-21: The ExPeCT Trial


Brady, L., B. Hayes, G. Sheill, A. M. Baird, E. Guinan, B. Stanfill, T. Vlajnic, O. Casey, V. Murphy, J. Greene, E. H. Allott, J. Hussey, F. Cahill, M. Van Hemelrijck, N. Peat, L. Mucci, M. Cunningham, L. Grogan, T. Lynch, R. P. Manecksha, J. McCaffrey, D. O’Donnell, O. Sheils, J. O’Leary, S. Rudman, R. McDermott & S. Finn (2020) “Platelet cloaking of circulating tumour cells in patients with metastatic prostate cancer: Results from ExPeCT, a randomised controlled trial.” PLoS One, 15, e0243928.
08-17: IMRT Prostate Cullen, D., J. Bryant, A. Maguire, D. Medipally, B. McClean, L. Shields, E. Noone, S. Bradshaw, M. Finn, M. Dunne, A. M. Shannon, J. Armstrong, O. Howe, A. D. Meade & F. M. Lyng (2020) “Raman spectroscopy of lymphocytes for the identification of prostate cancer patients with late radiation toxicity following radiotherapy.” Translational Biophotonics, e201900035, 2627-1850.
11-24: NSABP B47 Fehrenbacher, L., R. S. Cecchini, C. E. Geyer, P. Rastogi, J. P. Costantino, J. N. Atkins, J. P. Crown, J. Polikoff, J. F. Boileau, L. Provencher, C. Stokoe, T. D. Moore, A. Robidoux, P. J. Flynn, V. F. Borges, K. S. Albain, S. M. Swain, S. Paik, E. P. Mamounas and N. Wolmark (2020). “NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.J Clin Oncol 38(5): 444-453.
15-42: LOXO 101 Study Hong, D. S., S. G. DuBois, S. Kummar, A. F. Farago, C. M. Albert, K. S. Rohrberg, C. M. van Tilburg, R. Nagasubramanian, J. D. Berlin, N. Federman, L. Mascarenhas, B. Geoerger, A. Dowlati, A. S. Pappo, S. Bielack, F. Doz, R. McDermott, J. D. Patel, R. J. Schilder, M. Tahara, S. M. Pfister, O. Witt, M. Ladanyi, E. R. Rudzinski, S. Nanda, B. H. Childs, T. W. Laetsch, D. M. Hyman & A. Drilon (2020) “Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.” Lancet Oncol, 21, 531-540.
15-43: CRQ Survey Study Kearns, C., R. Feighery, J. Mc Caffrey, M. Higgins, M. Smith, V. Murphy, S. O’Reilly, A. M. Horgan, J. Walshe, R. McDermott, P. G. Morris, M. Keane, M. Martin, C. Murphy, K. Duffy, A. Mihai, J. Armstrong, D. M. O’Donnell, W. M. Gallagher & C. M. Kelly (2020) “Understanding and Attitudes toward Cancer Clinical Trials among Patients with a Cancer Diagnosis: National Study through Cancer Trials Ireland.” Cancers (Basel), 12.
06-15/97-01: Proteomic Prostate study/Prostate Keenan, L. G., N. Ibrahim, M. T. Dunne, M. Finn & J. G. Armstrong (2020) “The effect of anaemia on normal tissue toxicity and survival outcomes in prostate cancer treated with radical radiotherapy and neo-adjuvant androgen deprivation.” Br J Radiol, 93, 20190577.
14-12: MDV3100-12 Krop, I., V. Abramson, M. Colleoni, T. Traina, F. Holmes, L. Garcia-Estevez, L. Hart, A. Awada, C. Zamagni, P. G. Morris, L. Schwartzberg, S. Chan, A. Gucalp, L. Biganzoli, J. Steinberg, L. Sica, M. Trudeau, D. Markova, J. Tarazi, Z. Zhu, T. O’Brien, C. M. Kelly, E. Winer & D. A. Yardley (2020) “A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer.” Clin Cancer Res, 26, 6149-6157.
Lewison, G., A. Gavin, K. McCallion, R. McDermott, R. Sullivan & M. Lawler (2020) “The ‘Good Friday Agreement’ and cancer research on the island of Ireland: Evidence for the impact of a tripartite cancer research partnership.” Eur J Cancer, 129, 15-22.
10-11: Circulating miRNA’s McGuire, A., M. C. Casey, R. M. Waldron, H. Heneghan, O. Kalinina, E. Holian, A. McDermott, A. J. Lowery, J. Newell, R. M. Dwyer, N. Miller, M. Keane, J. A. L. Brown & M. J. Kerin (2020) “Prospective Assessment of Systemic MicroRNAs as Markers of Response to Neoadjuvant Chemotherapy in Breast Cancer.” Cancers (Basel), 12.
08-17: IMRT Prostate


Medipally, D. K. R., D. Cullen, V. Untereiner, J. Bryant, G. D. Sockalingum, T. N. Q. Nguyen, E. Noone, S. Bradshaw, M. Finn, M. Dunne, A. M. Shannon, J. Armstrong, A. D. Meade & F. M. Lyng (2020) “Effect of hemolysis on Fourier transform infrared and Raman spectra of blood plasma.” J Biophotonics, 13, e201960173.
08-17: IMRT Prostate


Medipally, D. K. R., D. Cullen, V. Untereiner, G. D. Sockalingum, A. Maguire, T. N. Q. Nguyen, J. Bryant, E. Noone, S. Bradshaw, M. Finn, M. Dunne, A. M. Shannon, J. Armstrong, A. D. Meade & F. M. Lyng (2020) “Vibrational spectroscopy of liquid biopsies for prostate cancer diagnosis.” Ther Adv Med Oncol, 12, 1758835920918499.
12-24 ETOP BELIEF Molina-Vila, M. A., R. A. Stahel, U. Dafni, N. Jordana-Ariza, A. Balada-Bel, M. Garzón-Ibáñez, B. García-Peláez, C. Mayo-de-Las-Casas, E. Felip, A. Curioni Fontecedro, O. Gautschi, S. Peters, B. Massutí, R. Palmero, S. Ponce Aix, E. Carcereny, M. Früh, M. Pless, S. Popat, S. Cuffe, P. Bidoli, R. Kammler, H. Roschitzki-Voser, Z. Tsourti, N. Karachaliou and R. Rosell (2020). “Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial. J Thorac Oncol 15(3): 416-425.
10-06: TROG DCIS


Olivotto, I. A., E. Link, C. Phillips, T. J. Whelan, G. Bryant, I. H. Kunkler, A. H. Westenberg, K. Purohit, V. Ahern, P. H. Graham, M. Akra, O. McArdle, J. J. Ludbrook, J. A. Harvey, J. H. Maduro, C. Kirkove, G. Gruber, J. D. Martin, I. D. Campbell, G. P. Delaney, B. H. Chua and B.-T. t. investigators (2020). “International comparison of cosmetic outcomes of breast conserving surgery and radiation therapy for women with ductal carcinoma in situ of the breast.” Radiother Oncol 142: 180-185.
12-53: ETOP SPLENDOUR Peters, S., S. Danson, B. Hasan, U. Dafni, N. Reinmuth, M. Majem, K. G. Tournoy, M. T. Mark, M. Pless, M. Cobo, D. Rodriguez-Abreu, L. Falchero, T. Moran, A. L. Ortega Granados, I. Monnet, K. Mohorcic, B. M. Sureda, D. Betticher, I. Demedts, J. A. Macias, S. Cuffe, A. Luciani, J. G. Sanchez, A. Curioni-Fontecedro, O. Gautschi, G. Price, L. Coate, R. von Moos, C. Zielinski, M. Provencio, J. Menis, B. Ruepp, A. Pochesci, H. Roschitzki-Voser, B. Besse, M. Rabaglio, M. E. R. O’Brien & R. A. Stahel (2020) “A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial.” J Thorac Oncol, 15, 1647-1656.
10-12: ANZGOG-0701 symptom benefit study Roncolato, F. T., R. L. O’Connell, F. Joly, A. Lanceley, F. Hilpert, L. Buizen, A. Okamoto, E. Aotani, V. Salutari, P. Donnellan, A. Oza, E. Avall-Lundqvist, J. Berek, T. Fehm, J. Ledermann, C. Roemer-Becuwe, M. R. Stockler, M. T. King and M. L. Friedlander (2020). “Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy – The GCIG symptom benefit study (SBS).” Gynecol Oncol 156(1): 45-53.
12-43: TRIO 022/ PALOMA-2


Rugo, H. S., R. S. Finn, K. Gelmon, A. A. Joy, N. Harbeck, A. Castrellon, H. Mukai, J. M. Walshe, A. Mori, E. Gauthier, D. R. Lu, E. Bananis, M. Martin & V. Diéras (2020) “Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2.” Clin Breast Cancer, 20, e173-e180.
06-31: TAILORx Study


Sparano, J. A., R. J. Gray, D. F. Makower, K. S. Albain, T. J. Saphner, S. S. Badve, L. I. Wagner, V. G. Kaklamani, M. M. Keane, H. L. Gomez, P. S. Reddy, T. F. Goggins, I. A. Mayer, D. L. Toppmeyer, A. M. Brufsky, M. P. Goetz, J. L. Berenberg, C. Mahalcioiu, C. Desbiens, D. F. Hayes, E. C. Dees, C. E. Geyer, J. A. Olson, W. C. Wood, T. Lively, S. Paik, M. J. Ellis, J. Abrams & G. W. Sledge (2020) “Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.” JAMA Oncol, 6, 367-374.
16-20: IBCSG 48-14 POSITIVE Sun, Z., S. M. Niman, O. Pagani, A. H. Partridge, H. A. Azim, F. A. Peccatori, M. Ruggeri, A. Di Leo, M. Colleoni, R. D. Gelber, M. M. Regan & P. S. Committee (2020) “Estimation of historical control rate for a single arm de-escalation study – Application to the POSITIVE trial”. Breast, 53, 1-7.

*Cancer Trials Ireland author (member of the Positive Steering committee) listed in the appendix

05-03: Spinal Cord Compression Thirion, P. G., M. T. Dunne, P. J. Kelly, A. Flavin, J. M. O’Sullivan, D. Hacking, W. Sasiadek, C. Small, M. M. Pomeroy, J. Martin, O. McArdle, I. Parker, L. S. O’Sullivan, A. M. Shannon, A. Clayton-Lea, C. D. Collins, M. R. Stevenson, A. Alvarez-Iglesias, J. G. Armstrong & M. Moriarty (2020) “Non-inferiority randomised phase 3 trial comparing two radiation schedules (single vs. five fractions) in malignant spinal cord compression.” Br J Cancer, 122, 1315-1323.
12-09: CharactHer Walsh, N., C. Andrieu, P. O’Donovan, C. Quinn, A. Maguire, S. J. Furney, G. Gullo & J. Crown (2020) “Whole-exome sequencing of long-term, never relapse exceptional responders of trastuzumab-treated HER2+ metastatic breast cancer.Br J Cancer, 123, 1219-1222.
Study Number: Short Name

2019 Journal Publications

11-29: ICON 8B Clamp, A. R., E. C. James, I. A. McNeish, A. Dean, J. W. Kim, D. M. O’Donnell, J. Hook, C. Coyle, S. Blagden, J. D. Brenton, R. Naik, T. Perren, S. Sundar, A. D. Cook, G. S. Gopalakrishnan, H. Gabra, R. Lord, G. Dark, H. M. Earl, M. Hall, S. Banerjee, R. M. Glasspool, R. Jones, S. Williams, A. M. Swart, S. Stenning, M. Parmar, R. Kaplan and J. A. Ledermann (2019). “Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.” Lancet 394(10214): 2084-2095.
14-06: ANZUP ENZAMET Study Davis, I. D., A. J. Martin, M. R. Stockler, S. Begbie, K. N. Chi, S. Chowdhury, X. Coskinas, M. Frydenberg, W. E. Hague, L. G. Horvath, A. M. Joshua, N. J. Lawrence, G. Marx, J. McCaffrey, R. McDermott, M. McJannett, S. A. North, F. Parnis, W. Parulekar, D. W. Pook, M. N. Reaume, S. K. Sandhu, A. Tan, T. H. Tan, A. Thomson, E. Tu, F. Vera-Badillo, S. G. Williams, S. Yip, A. Y. Zhang, R. R. Zielinski, C. J. Sweeney and E. T. I. a. t. A. a. N. Z. U. a. P. C. T. Group (2019). “Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.N Engl J Med 381(2): 121-131.
08-10: TC-Avastin Gullo, G., A. J Eustace, A. Canonici, D. M Collins, M. J. Kennedy, L. Grogan, O. Breathhnach, J. McCaffrey, M. Keane, M. J. Martin, R. Gupta, G. Leonard, M. O’Connor, P. M. Calvert, P. Donnellan, J. Walshe, E. McDermott, K. Scott, A. Hernando, I. Parker, D. W Murray, A. C O’Farrell, A. Maratha, P. Dicker, M. Rafferty, V. Murphy, N. O’Donovan, W. M Gallagher, B. Ky, D. Tryfonopoulos, B. Moulton, A. T Byrne and J. Crown (2019). “Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trial.Ther Adv Med Oncol 11: 1758835919864236.
06-35: PET-CT Lung Lee, K. A., G. Rangaswamy, N. A. Lavan, M. Dunne, C. D. Collins, C. Small and P. Thirion (2019). “ICORG 06-35: a prospective evaluation of PET-CT scan in patients with non-operable or non-resectable non-small cell lung cancer treated by radical 3-dimensional conformal radiation therapy: a phase II study.” Ir J Med Sci 188(4): 1155-1161.
06-32: NSABP 42


Mamounas, E. P., H. Bandos, B. C. Lembersky, J. H. Jeong, C. E. Geyer, P. Rastogi, L. Fehrenbacher, M. L. Graham, S. K. Chia, A. M. Brufsky, J. M. Walshe, G. S. Soori, S. R. Dakhil, T. E. Seay, J. L. Wade, E. C. McCarron, S. Paik, S. M. Swain, D. L. Wickerham and N. Wolmark (2019). “Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol 20(1): 88-99.
08-17: IMRT Prostate Medipally, D. K. R., T. N. Q. Nguyen, J. Bryant, V. Untereiner, G. D. Sockalingum, D. Cullen, E. Noone, S. Bradshaw, M. Finn, M. Dunne, A. M. Shannon, J. Armstrong, F. M. Lyng and A. D. Meade (2019). “Monitoring Radiotherapeutic Response in Prostate Cancer Patients Using High Throughput FTIR Spectroscopy of Liquid Biopsies.” Cancers (Basel) 11(7).
12-39: De-ESCALaTE HPV Mehanna, H., M. Robinson, A. Hartley, A. Kong, B. Foran, T. Fulton-Lieuw, M. Dalby, P. Mistry, M. Sen, L. O’Toole, H. Al Booz, K. Dyker, R. Moleron, S. Whitaker, S. Brennan, A. Cook, M. Griffin, E. Aynsley, M. Rolles, E. De Winton, A. Chan, D. Srinivasan, I. Nixon, J. Grumett, C. R. Leemans, J. Buter, J. Henderson, K. Harrington, C. McConkey, A. Gray, J. Dunn and D.-E. H. T. Group (2019). “Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.Lancet 393(10166): 51-60.
16-02: CyBorD-DARA O’Dwyer, M., R. Henderson, S. D. Naicker, M. R. Cahill, P. Murphy, V. Mykytiv, J. Quinn, C. McEllistrim, J. Krawczyk, J. Walsh, E. Lenihan, T. Kenny, A. Hernando, G. Hirakata, I. Parker, E. Kinsella, G. Gannon, A. Natoni, K. Lynch and A. E. Ryan (2019). “CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study.Blood Adv 3(12): 1815-1825.
01-04: BCIRG 005 Press, M. F., J. A. Seoane, C. Curtis, E. Quinaux, R. Guzman, G. Sauter, W. Eiermann, J. R. Mackey, N. Robert, T. Pienkowski, J. Crown, M. Martin, V. Valero, V. Bee, Y. Ma, I. Villalobos and D. J. Slamon (2019). “Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines.JAMA Oncol 5(3): 366-375.
14-13: MK3475-024 / KEYNOTE-024 Reck, M., D. Rodríguez-Abreu, A. G. Robinson, R. Hui, T. Csőszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O’Brien, S. Rao, K. Hotta, K. Vandormael, A. Riccio, J. Yang, M. C. Pietanza and J. R. Brahmer (2019). “Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. J Clin Oncol 37(7): 537-546.
15-10: OPTIMISMM Richardson, P. G., A. Oriol, M. Beksac, A. M. Liberati, M. Galli, F. Schjesvold, J. Lindsay, K. Weisel, D. White, T. Facon, J. San Miguel, K. Sunami, P. O’Gorman, P. Sonneveld, P. Robak, S. Semochkin, S. Schey, X. Yu, T. Doerr, A. Bensmaine, T. Biyukov, T. Peluso, M. Zaki, K. Anderson, M. Dimopoulos and O. t. investigators (2019). “Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.Lancet Oncol 20(6): 781-794.
15-05: UPCI 10-028 / Oligo recurrent Stereotactic Sutera, P., D. A. Clump, R. Kalash, D. D’Ambrosio, A. Mihai, H. Wang, D. P. Petro, S. A. Burton and D. E. Heron (2019). “Initial Results of a Multicenter Phase 2 Trial of Stereotactic Ablative Radiation Therapy for Oligometastatic Cancer.Int J Radiat Oncol Biol Phys 103(1): 116-122.
09-03: AGO-OVAR 16 (GSK: VEG110655) Vergote, I., A. du Bois, A. Floquet, J. Rau, J. W. Kim, J. M. Del Campo, M. Friedlander, S. Pignata, K. Fujiwara, N. Colombo, M. R. Mirza, B. J. Monk, I. Tsibulak, P. M. Calvert, T. J. Herzog, L. C. Hanker, J. Meunier, J. Y. Lee, A. Bologna, M. J. Carrasco-Alfonso and P. Harter (2019). “Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer.” Gynecol Oncol 155(2): 186-191.
Study Number: Short Name

2018 Journal Publications

07-01: CLL-IRL Appleby, N., D. O’Brien, F. M. Quinn, L. Smyth, J. Kelly, I. Parker, K. Scott, M. R. Cahill, G. Crotty, H. Enright, B. Hennessy, A. Hodgson, M. Leahy, H. O’Leary, M. O’Dwyer, A. Hayat and E. A. Vandenberghe (2018). “Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL.” Leuk Lymphoma 59(6): 1338-1347.
04-01: AZURE Brown, J., E. Rathbone, S. Hinsley, W. Gregory, F. Gossiel, H. Marshall, R. Burkinshaw, H. Shulver, H. Thandar, G. Bertelli, K. Maccon, A. Bowman, A. Hanby, R. Bell, D. Cameron and R. Coleman (2018). “Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial.” J Natl Cancer Inst 110(8): 871-879.
99-09: 3DCRT Lung


Cagney, D. N., P. G. Thirion, M. T. Dunne, C. Fleming, D. Fitzpatrick, C. M. O’Shea, M. A. Finn, S. O’Sullivan, C. Booth, C. D. Collins, S. J. Buckney, A. Shannon and J. G. Armstrong (2018). “A Phase II Toxicity End Point Trial (ICORG 99-09) of Accelerated Dose-escalated Hypofractionated Radiation in Non-small Cell Lung Cancer.” Clin Oncol (R Coll Radiol) 30(1): 30-38.
12-40: EORTC 10085 Cardoso, F., J. M. S. Bartlett, L. Slaets, C. H. M. van Deurzen, E. van Leeuwen-Stok, P. Porter, B. Linderholm, I. Hedenfalk, C. Schröder, J. Martens, J. Bayani, C. van Asperen, M. Murray, C. Hudis, L. Middleton, J. Vermeij, K. Punie, J. Fraser, M. Nowaczyk, I. T. Rubio, S. Aebi, C. Kelly, K. J. Ruddy, E. Winer, C. Nilsson, L. Dal Lago, L. Korde, K. Benstead, O. Bogler, T. Goulioti, A. Peric, S. Litière, K. C. Aalders, C. Poncet, K. Tryfonidis and S. H. Giordano (2018). “Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.” Ann Oncol 29(2): 405-417.
11-03: SOLE Colleoni, M., W. Luo, P. Karlsson, J. Chirgwin, S. Aebi, G. Jerusalem, P. Neven, E. Hitre, M. P. Graas, E. Simoncini, C. Kamby, A. Thompson, S. Loibl, J. Gavilá, K. Kuroi, C. Marth, B. Müller, S. O’Reilly, V. Di Lauro, A. Gombos, T. Ruhstaller, H. Burstein, K. Ribi, J. Bernhard, G. Viale, R. Maibach, M. Rabaglio-Poretti, R. D. Gelber, A. S. Coates, A. Di Leo, M. M. Regan, A. Goldhirsch and S. Investigators (2018). “Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.” Lancet Oncol 19(1): 127-138.
06-02: SOFT Francis, P. A., O. Pagani, G. F. Fleming, B. A. Walley, M. Colleoni, I. Láng, H. L. Gómez, C. Tondini, E. Ciruelos, H. J. Burstein, H. R. Bonnefoi, M. Bellet, S. Martino, C. E. Geyer, M. P. Goetz, V. Stearns, G. Pinotti, F. Puglisi, S. Spazzapan, M. A. Climent, L. Pavesi, T. Ruhstaller, N. E. Davidson, R. Coleman, M. Debled, S. Buchholz, J. N. Ingle, E. P. Winer, R. Maibach, M. Rabaglio-Poretti, B. Ruepp, A. Di Leo, A. S. Coates, R. D. Gelber, A. Goldhirsch, M. M. Regan and S. a. T. I. a. t. I. B. C. S. Group (2018). “Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.” N Engl J Med 379(2): 122-137.

* Cancer Trials Ireland authors listed in supplementary materials

09-03: AGO-OVA 16 (GSK: VEG110655) Friedlander, M., J. Rau, C. K. Lee, W. Meier, A. Lesoin, J. W. Kim, A. Poveda, M. Buck, G. Scambia, M. Shimada, F. Hilpert, M. T. King, P. Debruyne, A. Bologna, S. Malander, B. J. Monk, E. Petru, P. Calvert, T. J. Herzog, C. Barrett and A. du Bois (2018). “Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy.” Ann Oncol 29(3): 737-743.
12-45: SNAP Gennari, A., Z. Sun, U. Hasler-Strub, M. Colleoni, M. J. Kennedy, R. Von Moos, J. Cortés, M. J. Vidal, B. Hennessy, J. Walshe, K. A. Parraga, K. Ribi, J. Bernhard, S. M. Murillo, O. Pagani, A. Barbeaux, S. Borstnar, M. Rabaglio-Poretti, R. Maibach, M. M. Regan, G. Jerusalem and C. n. T. I. a. S. G. International Breast Cancer Study Group (2018). “A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial.” Ann Oncol 29(3): 661-668.
10-12: ANZGOG-0701 symptom benefit study King, M. T., M. R. Stockler, R. L. O’Connell, L. Buizen, F. Joly, A. Lanceley, F. Hilpert, A. Okamoto, E. Aotani, J. Bryce, P. Donnellan, A. Oza, E. Avall-Lundqvist, J. S. Berek, J. Sehouli, A. Feeney, D. Berton-Rigaud, D. S. J. Costa, M. L. Friedlander and G. S. B. group (2018). “Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer.” Qual Life Res 27(1): 59-74.
15-20: P3BEP Lawrence, N. J., H. Chan, G. Toner, M. R. Stockler, A. Martin, S. Yip, N. Wong, A. Yeung, D. Mazhar, F. Pashankar, L. Frazier, R. McDermott, R. Walker, H. Tan, I. D. Davis, P. Grimison and ANZUP (2018). “Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours.” BMC Cancer 18(1): 854.
05-03: Spinal Cord Compression Lee, K. A., M. Dunne, C. Small, P. J. Kelly, O. McArdle, J. O’Sullivan, D. Hacking, M. Pomeroy, J. Armstrong, M. Moriarty, A. Clayton-Lea, I. Parker, C. D. Collins and P. Thirion (2018). “(ICORG 05-03): prospective randomized non-inferiority phase III trial comparing two radiation schedules in malignant spinal cord compression (not proceeding with surgical decompression); the quality of life analysis.” Acta Oncol 57(7): 965-972.
08-17: IMRT Prostate Meade, A. D., A. Maguire, J. Bryant, D. Cullen, D. Medipally, L. White, B. McClean, L. Shields, J. Armstrong, M. Dunne, E. Noone, S. Bradshaw, M. Finn, A. M. Shannon, O. Howe and F. M. Lyng (2018). “Prediction of DNA damage and G2 chromosomal radio-sensitivity ex vivo in peripheral blood mononuclear cells with label-free Raman micro-spectroscopy.” Int J Radiat Biol: 1-10.
06-34: Palliative Lung McDermott, R. L., J. G. Armstrong, P. Thirion, M. Dunne, M. Finn, C. Small, M. Byrne, C. O’Shea, L. O’Sullivan, A. Shannon, E. Kelly and D. J. Hacking (2018). “Cancer Trials Ireland (ICORG) 06-34: A multi-centre clinical trial using three-dimensional conformal radiation therapy to reduce the toxicity of palliative radiation for lung cancer.” Radiother Oncol 127(2): 253-258.
05-04: Bladder-Filling Prostate Study Mullaney, L., E. O’Shea, M. T. Dunne, P. G. Thirion and J. G. Armstrong (2018). “A comparison of bladder volumes based on treatment planning CT and BladderScan® BVI 6100 ultrasound device in a prostate radiation therapy population.” Br J Radiol 91(1091): 20180160.


Newton, R. U., S. A. Kenfield, N. H. Hart, J. M. Chan, K. S. Courneya, J. Catto, S. P. Finn, R. Greenwood, D. C. Hughes, L. Mucci, S. R. Plymate, S. F. E. Praet, E. M. Guinan, E. L. Van Blarigan, O. Casey, M. Buzza, S. Gledhill, L. Zhang, D. A. Galvão, C. J. Ryan and F. Saad (2018). “Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol.” BMJ Open 8(5): e022899.
14-19: BMS CA209-142/CheckMate 142 Overman, M. J., S. Lonardi, K. Y. M. Wong, H. J. Lenz, F. Gelsomino, M. Aglietta, M. A. Morse, E. Van Cutsem, R. McDermott, A. Hill, M. B. Sawyer, A. Hendlisz, B. Neyns, M. Svrcek, R. A. Moss, J. M. Ledeine, Z. A. Cao, S. Kamble, S. Kopetz and T. André (2018). “Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.” J Clin Oncol 36(8): 773-779.
10-12: ANZGOG-0701 symptom benefit study Roncolato, F. T., D. Berton-Rigaud, R. O’Connell, A. Lanceley, J. Sehouli, L. Buizen, A. Okamoto, E. Aotani, D. Lorusso, P. Donnellan, A. Oza, E. Avall-Lundqvist, J. Berek, F. Hilpert, J. A. Ledermann, M. C. Kaminsky, M. R. Stockler, M. T. King and M. Friedlander (2018). “Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) – Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).” Gynecol Oncol 148(1): 36-41.
12-07: LCCC 1029 (Regorafenib)


Sanoff, H. K., R. M. Goldberg, A. Ivanova, S. O’Reilly, S. S. Kasbari, R. D. Kim, R. McDermott, D. T. Moore, W. Zamboni, W. Grogan, A. L. Cohn, T. S. Bekaii-Saab, G. Leonard, T. Ryan, O. O. Olowokure, N. H. Fernando, J. McCaffrey, B. F. El-Rayes, A. M. Horgan, G. B. Sherrill, G. H. Yacoub and B. H. O’Neil (2018). “Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.” Cancer 124(15): 3118-3126.


Smeets, D., I. S. Miller, D. P. O’Connor, S. Das, B. Moran, B. Boeckx, T. Gaiser, J. Betge, A. Barat, R. Klinger, N. C. T. van Grieken, C. Cremolini, H. Prenen, M. Mazzone, J. Depreeuw, O. Bacon, B. Fender, J. Brady, B. T. Hennessy, D. A. McNamara, E. Kay, H. M. Verheul, N. Maarten, W. M. Gallagher, V. Murphy, J. H. M. Prehn, M. Koopman, C. J. A. Punt, F. Loupakis, M. P. A. Ebert, B. Ylstra, D. Lambrechts and A. T. Byrne (2018). “Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy.” Nat Commun 9(1): 4112.
98-01: BIG 2-98 Sonnenblick, A., R. Salgado, S. Brohée, T. Zahavi, T. Peretz, G. Van den Eynden, G. Rouas, A. Salmon, P. A. Francis, A. Di Leo, J. P. A. Crown, G. Viale, L. Daly, B. Javdan, S. Fujisawa, E. De Azambuja, A. Lieveke, M. J. Piccart, J. F. Bromberg and C. Sotiriou (2018). “p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial.” Int J Oncol 52(2): 424-432.
06-31: TAILORx Sparano, J. A., R. J. Gray, D. F. Makower, K. I. Pritchard, K. S. Albain, D. F. Hayes, C. E. Geyer, E. C. Dees, M. P. Goetz, J. A. Olson, T. Lively, S. S. Badve, T. J. Saphner, L. I. Wagner, T. J. Whelan, M. J. Ellis, S. Paik, W. C. Wood, P. M. Ravdin, M. M. Keane, H. L. Gomez Moreno, P. S. Reddy, T. F. Goggins, I. A. Mayer, A. M. Brufsky, D. L. Toppmeyer, V. G. Kaklamani, J. L. Berenberg, J. Abrams and G. W. Sledge (2018). “Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.” N Engl J Med 379(2): 111-121.
12-16: AC-ANGIOPREDICT van Dijk, E., H. D. Biesma, M. Cordes, D. Smeets, M. Neerincx, S. Das, P. P. Eijk, V. Murphy, A. Barat, O. Bacon, J. H. M. Prehn, J. Betge, T. Gaiser, B. Fender, G. A. Meijer, D. A. McNamara, R. Klinger, M. Koopman, M. P. A. Ebert, E. W. Kay, B. T. Hennessey, H. M. W. Verheul, W. M. Gallagher, D. P. O’Connor, C. J. A. Punt, F. Loupakis, D. Lambrechts, A. T. Byrne, N. C. T. van Grieken and B. Ylstra (2018). “Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab.” J Clin Oncol 36(20): 2052-2060.
Study Number: Short Name

2017 Journal Publications

14-13: MSD MK-3475-024 / KEYNOTE-024 Brahmer, J. R., D. Rodríguez-Abreu, A. G. Robinson, R. Hui, T. Csőszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O’Brien, S. Rao, K. Hotta, J. Zhang, G. M. Lubiniecki, A. C. Deitz, R. Rangwala and M. Reck (2017). “Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.Lancet Oncol 18(12): 1600-1609.
97-01: Prostate, 02-01: Iressa Prostate, 05-04: Bladder-Filling Prostate study, 06-15: Proteomic Prostate study, 06-16: 3-D CRT vs. IMRT study, 08-17: IMRT Prostate


Cagney, D. N., M. Dunne, C. O’Shea, M. Finn, E. Noone, M. Sheehan, L. McDonagh, L. O’Sullivan, P. Thirion and J. Armstrong (2017). “Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy.” BMC Urol 17(1): 60.
04-02: TANGO Earl, H. M., L. Hiller, H. C. Howard, J. A. Dunn, J. Young, S. J. Bowden, M. McDermaid, A. K. Waterhouse, G. Wilson, R. Agrawal, S. O’Reilly, A. Bowman, D. M. Ritchie, A. Goodman, T. Hickish, K. McAdam, D. Cameron, D. Dodwell, D. W. Rea, C. Caldas, E. Provenzano, J. E. Abraham, P. Canney, J. P. Crown, M. J. Kennedy, R. Coleman, R. C. Leonard, J. A. Carmichael, A. M. Wardley, C. J. Poole and t. t. collaborators (2017). “Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.” Lancet Oncol 18(6): 755-769.
Karam, A., J. A. Ledermann, J. W. Kim, J. Sehouli, K. Lu, C. Gourley, N. Katsumata, R. A. Burger, B. H. Nam, M. Bacon, C. Ng, J. Pfisterer, R. L. M. Bekkers, A. Casado Herráez, A. Redondo, H. Fujiwara, N. Gleeson, O. Rosengarten, G. Scambia, J. Zhu, A. Okamoto, G. Stuart, K. Ochiai and p. o. t. t. O. C. C. Conference (2017). “Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions.Ann Oncol 28(4): 711-717.
08-17: IMRT Prostate Medipally, D. K., A. Maguire, J. Bryant, J. Armstrong, M. Dunne, M. Finn, F. M. Lyng and A. D. Meade (2017). “Development of a high throughput (HT) Raman spectroscopy method for rapid screening of liquid blood plasma from prostate cancer patients.Analyst 142(8): 1216-1226.
12-16: AC-ANGIOPREDICT Moran, B., S. Das, D. Smeets, G. Peutman, R. Klinger, B. Fender, K. Connor, M. Ebert, T. Gaiser, J. H. Prehn, O. Bacon, E. Kay, B. Hennessy, V. Murphy, B. Ylstra, D. Lambrechts, A. T. Byrne, W. M. Gallagher and D. P. O’Connor (2017). “Assessment of concordance between fresh-frozen and formalin-fixed paraffin embedded tumor DNA methylation using a targeted sequencing approach.” Oncotarget 8(29): 48126-48137.
11-05: GSK VEG113387 adjuvant pazopanib RCC study


Motzer, R. J., N. B. Haas, F. Donskov, M. Gross-Goupil, S. Varlamov, E. Kopyltsov, J. L. Lee, B. Melichar, B. I. Rini, T. K. Choueiri, M. Zemanova, L. A. Wood, M. N. Reaume, A. Stenzl, S. Chowdhury, H. Y. Lim, R. McDermott, A. Michael, W. Bao, M. J. Carrasco-Alfonso, P. Aimone, M. Voi, C. Doehn, P. Russo, C. N. Sternberg and P. investigators (2017). “Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.” J Clin Oncol 35(35): 3916-3923.
14-19: BMS CA209-142/CheckMate 142


Overman, M. J., R. McDermott, J. L. Leach, S. Lonardi, H. J. Lenz, M. A. Morse, J. Desai, A. Hill, M. Axelson, R. A. Moss, M. V. Goldberg, Z. A. Cao, J. M. Ledeine, G. A. Maglinte, S. Kopetz and T. André (2017). “Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.” Lancet Oncol 18(9): 1182-1191.


Peters, S., R. A. Stahel, U. Dafni, S. Ponce Aix, B. Massuti, O. Gautschi, L. Coate, A. Lopez Martin, R. van Heemst, T. Berghmans, P. Meldgaard, M. Cobo Dols, J. Garde Noguera, A. Curioni-Fontecedro, D. Rauch, M. T. Mark, S. Cuffe, B. Biesma, A. M. van Henten, O. Juan Vidal, R. Palmero Sanchez, J. C. Villa Guzman, R. Collado Martin, S. Peralta, A. Insa, Y. Summers, I. Lang, A. Horgan, F. Ciardiello, S. de Hosson, R. Pieterman, H. J. Groen, P. M. van den Berg, C. C. Zielinski, Y. Chittazhathu Kurian Kuruvilla, A. Gasca-Ruchti, M. Kassapian, S. Novello, V. Torri, Z. Tsourti, V. Gregorc, E. F. Smit and E. M.-l. C. Group (2017). “Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.” J Thorac Oncol 12(4): 752-762.
09-11: PAVES Pinter, T., Z. Klippel, A. Cesas, A. Croitoru, J. Decaestecker, P. Gibbs, Y. Hotko, J. Jassem, G. Kurteva, J. Novotny, S. O’Reilly, T. Salek, M. Reiner, P. K. Morrow, M. R. Choi, S. Whittaker and C. Blanke (2016). “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES).” Clin Colorectal Cancer 16(2): 103-114.e103.
10-14: Neo-AEGIS Reynolds, J. V., S. R. Preston, B. O’Neill, L. Baeksgaard, S. M. Griffin, C. Mariette, S. Cuffe, M. Cunningham, T. Crosby, I. Parker, K. Hofland, G. Hanna, L. B. Svendsen, C. L. Donohoe, C. Muldoon, D. O’Toole, C. Johnson, N. Ravi, G. Jones, A. K. Corkhill, M. Illsley, J. Mellor, K. Lee, M. Dib, V. Marchesin, M. Cunnane, K. Scott, P. Lawner, S. Warren, S. O’Reilly, G. O’Dowd, G. Leonard, B. Hennessy and R. M. Dermott (2017). “ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS).” BMC Cancer 17(1): 401.
10-12: ANZGOG-0701 symptom benefit study


Roncolato, F. T., F. Joly, R. O’Connell, A. Lanceley, F. Hilpert, L. Buizen, A. Okamoto, E. Aotani, S. Pignata, P. Donnellan, A. Oza, E. Avall-Lundqvist, J. S. Berek, F. Heitz, A. Feeney, D. Berton-Rigaud, M. R. Stockler, M. King, M. Friedlander and G. S. B. group (2017). “Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.” Oncologist 22(9): 1117-1124.


Rosell, R., U. Dafni, E. Felip, A. Curioni-Fontecedro, O. Gautschi, S. Peters, B. Massutí, R. Palmero, S. P. Aix, E. Carcereny, M. Früh, M. Pless, S. Popat, A. Kotsakis, S. Cuffe, P. Bidoli, A. Favaretto, P. Froesch, N. Reguart, J. Puente, L. Coate, F. Barlesi, D. Rauch, M. Thomas, C. Camps, J. Gómez-Codina, M. Majem, R. Porta, R. Shah, E. Hanrahan, R. Kammler, B. Ruepp, M. Rabaglio, M. Kassapian, N. Karachaliou, R. Tam, D. S. Shames, M. A. Molina-Vila, R. A. Stahel and B. c. group (2017). “Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.” Lancet Respir Med 5(5): 435-444.
15-21: The ExPeCT Trial


Sheill, G., L. Brady, E. Guinan, B. Hayes, O. Casey, J. Greene, T. Vlajnic, F. Cahill, M. Van Hemelrijck, N. Peat, S. Rudman, J. Hussey, M. Cunningham, L. Grogan, T. Lynch, R. P. Manecksha, J. McCaffrey, L. Mucci, O. Sheils, J. O’Leary, D. M. O’Donnell, R. McDermott and S. Finn (2017). “The ExPeCT (Examining Exercise, Prostate Cancer and Circulating Tumour Cells) trial: study protocol for a randomised controlled trial.” Trials 18(1): 456.
07-02: ALTTO


Sonnenblick, A., D. Agbor-Tarh, I. Bradbury, S. Di Cosimo, H. A. Azim, D. Fumagalli, S. Sarp, A. C. Wolff, M. Andersson, J. Kroep, T. Cufer, S. D. Simon, P. Salman, M. Toi, L. Harris, J. Gralow, M. Keane, A. Moreno-Aspitia, M. Piccart-Gebhart and E. de Azambuja (2017). “Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.” J Clin Oncol 35(13): 1421-1429.
13-02: BMS CA209-067 / CheckMate 067 Sznol, M., P. F. Ferrucci, D. Hogg, M. B. Atkins, P. Wolter, M. Guidoboni, C. Lebbé, J. M. Kirkwood, J. Schachter, G. A. Daniels, J. Hassel, J. Cebon, W. Gerritsen, V. Atkinson, L. Thomas, J. McCaffrey, D. Power, D. Walker, R. Bhore, J. Jiang, F. S. Hodi and J. D. Wolchok (2017). “Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.” J Clin Oncol: JCO2016721167.
10-05: TCHL Toomey, S., A. J. Eustace, J. Fay, K. M. Sheehan, A. Carr, M. Milewska, S. F. Madden, A. Teiserskiene, E. W. Kay, N. O’Donovan, W. Gallagher, L. Grogan, O. Breathnach, J. Walshe, C. Kelly, B. Moulton, M. J. Kennedy, G. Gullo, A. D. Hill, C. Power, D. Duke, N. Hambly, J. Crown and B. T. Hennessy (2017). “Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.” Breast Cancer Res 19(1): 87.
06-36: ECOG E1505 Wakelee, H. A., S. E. Dahlberg, S. M. Keller, W. J. Tester, D. R. Gandara, S. L. Graziano, A. A. Adjei, N. B. Leighl, S. C. Aisner, J. M. Rothman, J. D. Patel, M. D. Sborov, S. R. McDermott, R. Perez-Soler, A. M. Traynor, C. Butts, T. Evans, A. Shafqat, A. E. Chapman, S. S. Kasbari, L. Horn, S. S. Ramalingam, J. H. Schiller and ECOG-ACRIN (2017). “Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.Lancet Oncol 18(12): 1610-1623.
97-01: Prostate Xie, W., M. M. Regan, M. Buyse, S. Halabi, P. W. Kantoff, O. Sartor, H. Soule, N. W. Clarke, L. Collette, J. J. Dignam, K. Fizazi, W. R. Paruleker, H. M. Sandler, M. R. Sydes, B. Tombal, S. G. Williams, C. J. Sweeney and I. W. Group (2017). “Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.J Clin Oncol 35(27): 3097-3104.

* Cancer Trials Ireland author listed in supplementary materials

Study Number: Short Name

2016 Journal Publications

12-16: AC-ANGIOPREDICT Betge, J., A. Barat, V. Murphy, T. Hielscher, N. C. Van Grieken, S. Belle, T. Zhan, N. Härtel, M. Kripp, O. Bacon, M. Cordes, E. W. Kay, H. M. Verheul, M. Neerincx, B. Hennessy, R. D. Hofheinz, T. Gaiser, B. Ylstra, J. H. Prehn, D. Lambrechts, A. T. Byrne, M. P. Ebert and N. Schulte (2016). “Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative.” Digestion 94(3): 129-137.
02-04: EORTC Prostate Bolla, M., P. Maingon, C. Carrie, S. Villa, P. Kitsios, P. M. Poortmans, S. Sundar, E. M. van der Steen-Banasik, J. Armstrong, J. F. Bosset, F. G. Herrera, B. Pieters, A. Slot, A. Bahl, R. Ben-Yosef, D. Boehmer, C. Scrase, L. Renard, E. Shash, C. Coens, A. C. van den Bergh and L. Collette (2016). “Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991.” J Clin Oncol 34(15): 1748-1756.
08-18: CHHiP Study Dearnaley, D., I. Syndikus, H. Mossop, V. Khoo, A. Birtle, D. Bloomfield, J. Graham, P. Kirkbride, J. Logue, Z. Malik, J. Money-Kyrle, J. M. O’Sullivan, M. Panades, C. Parker, H. Patterson, C. Scrase, J. Staffurth, A. Stockdale, J. Tremlett, M. Bidmead, H. Mayles, O. Naismith, C. South, A. Gao, C. Cruickshank, S. Hassan, J. Pugh, C. Griffin, E. Hall and C. H. Investigators (2016). “Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.” Lancet Oncol 17(8): 1047-1060.
09-01: TRIO 018 Finn, R. S., J. P. Crown, J. Ettl, M. Schmidt, I. M. Bondarenko, I. Lang, T. Pinter, K. Boer, R. Patel, S. Randolph, S. T. Kim, X. Huang, P. Schnell, S. Nadanaciva, C. H. Bartlett and D. J. Slamon (2016). “Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.Breast Cancer Res 18(1): 67.
12-43: TRIO 022/ PALOMA-2 Finn, R. S., M. Martin, H. S. Rugo, S. Jones, S. A. Im, K. Gelmon, N. Harbeck, O. N. Lipatov, J. M. Walshe, S. Moulder, E. Gauthier, D. R. Lu, S. Randolph, V. Dieras and D. J. Slamon (2016). “Palbociclib and Letrozole in Advanced Breast Cancer.” N Engl J Med 375(20): 1925-1936.
05-09: IBIS-II Forbes, J. F., I. Sestak, A. Howell, B. Bonanni, N. Bundred, C. Levy, G. von Minckwitz, W. Eiermann, P. Neven, M. Stierer, C. Holcombe, R. E. Coleman, L. Jones, I. Ellis, J. Cuzick and I.-I. investigators (2016). “Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.” Lancet 387(10021): 866-873.
09-03: AGO-OVA 16 (GSK: VEG110655) Harter, P., T. Johnson, D. Berton-Rigaud, S. Y. Park, M. Friedlander, J. M. Del Campo, M. Shimada, F. Forget, M. R. Mirza, N. Colombo, C. Zamagni, J. K. Chan, M. Imhof, T. J. Herzog, D. O’Donnell, F. Heitz, K. King, S. Stinnett, C. Barrett, M. Jobanputra, C. F. Xu and A. du Bois (2016). “BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.” Gynecol Oncol 140(3): 443-449.
01-04: BCIRG 005 Press, M. F., G. Sauter, M. Buyse, H. Fourmanoir, E. Quinaux, D. D. Tsao-Wei, W. Eiermann, N. Robert, T. Pienkowski, J. Crown, M. Martin, V. Valero, J. R. Mackey, V. Bee, Y. Ma, I. Villalobos, A. Campeau, M. Mirlacher, M. A. Lindsay and D. J. Slamon (2016). “HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.” J Clin Oncol 34(29): 3518-3528.
09-03: AGO-OVA 16 (GSK: VEG110655) Pulford, D. J., P. Harter, A. Floquet, C. Barrett, D. H. Suh, M. Friedlander, J. A. Arranz, K. Hasegawa, H. Tada, P. Vuylsteke, M. R. Mirza, N. Donadello, G. Scambia, T. Johnson, C. Cox, J. K. Chan, M. Imhof, T. J. Herzog, P. Calvert, P. Wimberger, D. Berton-Rigaud, M. C. Lim, G. Elser, C. F. Xu and A. du Bois (2016). “Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study.” BMC Med Ethics 17(1): 63.
14-13: MK3475-024/KEYNOTE-024 Reck, M., D. Rodriguez-Abreu, A. G. Robinson, R. Hui, T. Csoszi, A. Fulop, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O’Brien, S. Rao, K. Hotta, M. A. Leiby, G. M. Lubiniecki, Y. Shentu, R. Rangwala, J. R. Brahmer and K.-. Investigators (2016). “Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.” N Engl J Med 375(19): 1823-1833.
06-02: SOFT Regan, M. M., P. A. Francis, O. Pagani, G. F. Fleming, B. A. Walley, G. Viale, M. Colleoni, I. Lang, H. L. Gomez, C. Tondini, G. Pinotti, K. N. Price, A. S. Coates, A. Goldhirsch and R. D. Gelber (2016). “Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.” J Clin Oncol 34(19): 2221-2231.
Scott, K., P. J. Hayden, A. Will, K. Wheatley and I. Coyne (2016). “Bortezomib for the treatment of multiple myeloma.” Cochrane Database Syst Rev 4: CD010816.
10-05: TCHL Toomey, S., A. J. Eustace, L. B. Pritzker, K. P. Pritzker, J. Fay, A. O’Grady, R. Cummins, L. Grogan, J. Kennedy, D. O’Connor, L. Young, E. W. Kay, N. O’Donovan, W. M. Gallagher, R. Kalachand, J. Crown and B. T. Hennessy (2016). “RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.” J Natl Cancer Inst 108(8).
Study Number: Short Name

2015 Journal Publications

09-01: TRIO 018 Finn, R. S., J. P. Crown, I. Lang, K. Boer, I. M. Bondarenko, S. O. Kulyk, J. Ettl, R. Patel, T. Pinter, M. Schmidt, Y. Shparyk, A. R. Thummala, N. L. Voytko, C. Fowst, X. Huang, S. T. Kim, S. Randolph and D. J. Slamon (2015). “The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.” Lancet Oncol 16(1): 25-35.
09-03: AGO-OVA 16 (GSK: VEG110655) Floquet, A., I. Vergote, N. Colombo, B. Fiane, B. J. Monk, A. Reinthaller, P. Calvert, T. J. Herzog, W. Meier, J. W. Kim, J. M. del Campo, M. Friedlander, C. Pisano, S. Isonishi, R. J. Crescenzo, C. Barrett, K. Wang, I. Mitrica and A. du Bois (2015). “Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial.” Gynecol Oncol 136(1): 37-42.
08-09: Patient Customised Headrest Study Howlin, C., E. O’Shea, M. Dunne, L. Mullaney, M. McGarry, A. Clayton-Lea, M. Finn, P. Carter, B. Garret and P. Thirion (2015). “A randomized controlled trial comparing customized versus standard headrests for head and neck radiotherapy immobilization in terms of set-up errors, patient comfort and staff satisfaction (ICORG 08-09).” Radiography 21(1): 74-83.
08-10: TC-Avastin Sparano, J. A., R. J. Gray, D. F. Makower, K. I. Pritchard, K. S. Albain, D. F. Hayes, C. E. Geyer, Jr., E. C. Dees, E. A. Perez, J. A. Olson, Jr., J. Zujewski, T. Lively, S. S. Badve, T. J. Saphner, L. I. Wagner, T. J. Whelan, M. J. Ellis, S. Paik, W. C. Wood, P. Ravdin, M. M. Keane, H. L. Gomez Moreno, P. S. Reddy, T. F. Goggins, I. A. Mayer, A. M. Brufsky, D. L. Toppmeyer, V. G. Kaklamani, J. N. Atkins, J. L. Berenberg and G. W. Sledge (2015). “Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.” N Engl J Med 373(21): 2005-2014.
06-15: Proteomic Prostate Study Tonry, C. L., D. Doherty, C. O’Shea, B. Morrissey, L. Staunton, B. Flatley, A. Shannon, J. Armstrong and S. R. Pennington (2015). “Discovery and Longitudinal Evaluation of Candidate Protein Biomarkers for Disease Recurrence in Prostate Cancer.” J Proteome Res 14(7): 2769-2783.
Study Number: Short Name

2014 Journal Publications

97-01: Prostate Barry, A. S., M. T. Dunne, C. A. Lyons, M. A. Finn, B. Moulton, J. C. Taylor, C. M. O’Shea, P. G. Thirion and J. G. Armstrong (2014). “Temporal patterns of late bowel and bladder radiotherapy toxicity in a randomised controlled trial assessing duration of neo-adjuvant hormones in prostate cancer.” Acta Oncol 53(10): 1390-1397.
05-09: IBIS-II Cuzick, J., I. Sestak, J. F. Forbes, M. Dowsett, J. Knox, S. Cawthorn, C. Saunders, N. Roche, R. E. Mansel, G. von Minckwitz, B. Bonanni, T. Palva, A. Howell and I.-I. investigators (2014). “Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.” Lancet 383(9922): 1041-1048.
05-04: Bladder-Filling Prostate Study Mullaney, L. M., E. O’Shea, M. T. Dunne, M. A. Finn, P. G. Thirion, L. A. Cleary, M. McGarry, L. O’Neill and J. G. Armstrong (2014). “A randomized trial comparing bladder volume consistency during fractionated prostate radiation therapy.” Pract Radiat Oncol 4(5): e203-212.
Study Number: Short Name

2013 Journal Publications

08-20: BMS CA180227 (READY) Study: Taxotere+/- Dasatinib in Hormone Refractory Prostate Cancer Araujo, J. C., G. C. Trudel, F. Saad, A. J. Armstrong, E. Y. Yu, J. Bellmunt, G. Wilding, J. McCaffrey, S. V. Serrano, V. B. Matveev, E. Efstathiou, S. Oudard, M. J. Morris, B. Sizer, P. J. Goebell, A. Heidenreich, J. S. de Bono, S. Begbie, J. H. Hong, E. Richardet, E. Gallardo, P. Paliwal, S. Durham, S. Cheng and C. J. Logothetis (2013). “Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.” Lancet Oncol 14(13): 1307-1316.
01-03: BCIRG 006 Au, H. J., W. Eiermann, N. J. Robert, T. Pienkowski, J. Crown, M. Martin, M. Pawlicki, A. Chan, J. Mackey, J. Glaspy, T. Pinter, M. C. Liu, T. Fornander, S. Sehdev, J. M. Ferrero, V. Bee, M. J. Santana, D. P. Miller, D. Lalla, D. J. Slamon and B. T. I. Translational Research in Oncology (2013). “Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study.” Oncologist 18(7): 812-818.
05-10: Velcade Meso Busacca, S., A. D. Chacko, A. Klabatsa, K. Arthur, M. Sheaff, D. Barbone, L. Mutti, V. K. Gunasekharan, J. J. Gorski, M. El-Tanani, V. C. Broaddus, G. Gaudino and D. A. Fennell (2013). “BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma.” PLoS One 8(6): e65489.
06-04: EGF100161 Crown, J., M. J. Kennedy, P. Tresca, M. Marty, M. Espie, H. A. Burris, M. DeSilvio, M. R. Lau, D. Kothari, K. M. Koch and V. Dieras (2013). “Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer.” Ann Oncol 24(8): 2005-2011.
07-08: A6181099 Crown, J. P., V. Dieras, E. Staroslawska, D. A. Yardley, T. Bachelot, N. Davidson, H. Wildiers, P. A. Fasching, O. Capitain, M. Ramos, R. Greil, F. Cognetti, G. Fountzilas, M. Blasinska-Morawiec, C. Liedtke, R. Kreienberg, W. H. Miller, Jr., V. Tassell, X. Huang, J. Paolini, K. A. Kern and G. Romieu (2013). “Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.” J Clin Oncol 31(23): 2870-2878.
06-14: Prosty Kellokumpu-Lehtinen, P. L., U. Harmenberg, T. Joensuu, R. McDermott, P. Hervonen, C. Ginman, M. Luukkaa, P. Nyandoto, A. Hemminki, S. Nilsson, J. McCaffrey, R. Asola, T. Turpeenniemi-Hujanen, F. Laestadius, T. Tasmuth, K. Sandberg, M. Keane, I. Lehtinen, T. Luukkaala, H. Joensuu and P. s. group (2013). “2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.” Lancet Oncol 14(2): 117-124.
98-01: BIG 2-98 Loi, S., N. Sirtaine, F. Piette, R. Salgado, G. Viale, F. Van Eenoo, G. Rouas, P. Francis, J. P. Crown, E. Hitre, E. de Azambuja, E. Quinaux, A. Di Leo, S. Michiels, M. J. Piccart and C. Sotiriou (2013). “Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.” J Clin Oncol 31(7): 860-867.
06-15: Proteomic Prostate Study Morrissey, B., C. O’Shea, J. Armstrong, C. Rooney, L. Staunton, M. Sheehan, A. M. Shannon and S. R. Pennington (2013). “Development of a label-free LC-MS/MS strategy to approach the identification of candidate protein biomarkers of disease recurrence in prostate cancer patients in a clinical trial of combined hormone and radiation therapy.” Proteomics Clin Appl 7(5-6): 316-326.
97-01: Prostate Mydin, A. R., M. T. Dunne, M. A. Finn and J. G. Armstrong (2013). “Early salvage hormonal therapy for biochemical failure improved survival in prostate cancer patients after neoadjuvant hormonal therapy plus radiation therapy–a secondary analysis of irish clinical oncology research group 97-01.” Int J Radiat Oncol Biol Phys 85(1): 101-108.
98-01: BIG 2-98 Oakman, C., P. A. Francis, J. Crown, E. Quinaux, M. Buyse, E. De Azambuja, M. Margeli Vila, M. Andersson, B. Nordenskjold, R. Jakesz, B. Thurlimann, J. Gutierrez, V. Harvey, L. Punzalan, P. Dell’orto, D. Larsimont, I. Steinberg, R. D. Gelber, M. Piccart-Gebhart, G. Viale and A. Di Leo (2013). “Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer–8-year results of the Breast International Group 02-98 phase III trial.” Ann Oncol 24(5): 1203-1211.
05-02: NSABP C08 Pogue-Geile, K., G. Yothers, Y. Taniyama, N. Tanaka, P. Gavin, L. Colangelo, N. Blackmon, C. Lipchik, S. R. Kim, S. Sharif, C. Allegra, N. Petrelli, M. J. O’Connell, N. Wolmark and S. Paik (2013). “Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08.” J Natl Cancer Inst 105(13): 989-992.
10-18: A8081007 Shaw, A. T., D. W. Kim, K. Nakagawa, T. Seto, L. Crino, M. J. Ahn, T. De Pas, B. Besse, B. J. Solomon, F. Blackhall, Y. L. Wu, M. Thomas, K. J. O’Byrne, D. Moro-Sibilot, D. R. Camidge, T. Mok, V. Hirsh, G. J. Riely, S. Iyer, V. Tassell, A. Polli, K. D. Wilner and P. A. Janne (2013). “Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.” N Engl J Med 368(25): 2385-2394.
05-11: NSABP B38 Swain, S. M., G. Tang, C. E. Geyer, Jr., P. Rastogi, J. N. Atkins, P. P. Donnellan, L. Fehrenbacher, C. A. Azar, A. Robidoux, J. A. Polikoff, A. M. Brufsky, D. D. Biggs, E. A. Levine, J. L. Zapas, L. Provencher, D. W. Northfelt, S. Paik, J. P. Costantino, E. P. Mamounas and N. Wolmark (2013). “Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.” J Clin Oncol 31(26): 3197-3204.
Study Number: Short Name

2012 Journal Publications

06-22: Trastuzumab Biomarker Study Browne, B. C., A. J. Eustace, S. Kennedy, N. A. O’Brien, K. Pedersen, M. S. McDermott, A. Larkin, J. Ballot, T. Mahgoub, F. Sclafani, S. Madden, J. Kennedy, M. J. Duffy, J. Crown and N. O’Donovan (2012). “Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.” Breast Cancer Res Treat 136(3): 717-727.
08-08: Biomarkers of Response to Taxotere in HRPC Corcoran, C., S. Rani, K. O’Brien, A. O’Neill, M. Prencipe, R. Sheikh, G. Webb, R. McDermott, W. Watson, J. Crown and L. O’Driscoll (2012). “Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes.” PLoS One 7(12): e50999.
97-01: Prostate Daly, P. E., M. T. Dunne, C. M. O’Shea, M. A. Finn and J. G. Armstrong (2012). “The effect of short term neo-adjuvant androgen deprivation on erectile function in patients treated with external beam radiotherapy for localised prostate cancer: an analysis of the 4- versus 8-month randomised trial (Irish Clinical Oncology Research Group 97-01).” Radiother Oncol 104(1): 96-102.
07-12: Collaborative Biomarker Study Dowling, P., C. Clarke, K. Hennessy, B. Torralbo-Lopez, J. Ballot, J. Crown, I. Kiernan, K. J. O’Byrne, M. J. Kennedy, V. Lynch and M. Clynes (2012). “Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer.” Int J Cancer 131(4): 911-923.
05-10: Velcade Meso Fennell, D. A., C. McDowell, S. Busacca, G. Webb, B. Moulton, A. Cakana, K. J. O’Byrne, J. V. Meerbeeck, P. Donnellan, J. McCaffrey and P. Baas (2012). “Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma.” J Thorac Oncol 7(9): 1466-1470.
08-21: Cougar Phase III Study COU-AA-301 Fizazi, K., H. I. Scher, A. Molina, C. J. Logothetis, K. N. Chi, R. J. Jones, J. N. Staffurth, S. North, N. J. Vogelzang, F. Saad, P. Mainwaring, S. Harland, O. B. Goodman, Jr., C. N. Sternberg, J. H. Li, T. Kheoh, C. M. Haqq, J. S. de Bono and C.-A.-. Investigators (2012). “Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.” Lancet Oncol 13(10): 983-992.
Study Number: Short Name

2011 Journal Publications

06-07: Coin Adams, R. A., A. M. Meade, M. T. Seymour, R. H. Wilson, A. Madi, D. Fisher, S. L. Kenny, E. Kay, E. Hodgkinson, M. Pope, P. Rogers, H. Wasan, S. Falk, S. Gollins, T. Hickish, E. M. Bessell, D. Propper, M. J. Kennedy, R. Kaplan, T. S. Maughan and M. C. T. Investigators (2011). “Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.” Lancet Oncol 12(7): 642-653.
05-02: NSABP C08 Allegra, C. J., G. Yothers, M. J. O’Connell, S. Sharif, N. J. Petrelli, L. H. Colangelo, J. N. Atkins, T. E. Seay, L. Fehrenbacher, R. M. Goldberg, S. O’Reilly, L. Chu, C. A. Azar, S. Lopa and N. Wolmark (2011). “Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.” J Clin Oncol 29(1): 11-16.
97-01: Prostate Armstrong, J. G., C. M. Gillham, M. T. Dunne, D. A. Fitzpatrick, M. A. Finn, M. E. Cannon, J. C. Taylor, C. M. O’Shea, S. J. Buckney and P. G. Thirion (2011). “A randomized trial (Irish clinical oncology research group 97-01) comparing short versus protracted neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer.” Int J Radiat Oncol Biol Phys 81(1): 35-45.
04-01: AZURE Coleman, R., E. Woodward, J. Brown, D. Cameron, R. Bell, D. Dodwell, M. Keane, M. Gil, C. Davies, R. Burkinshaw, S. J. Houston, R. J. Grieve, P. J. Barrett-Lee and H. Thorpe (2011). “Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.” Breast Cancer Res Treat 127(2): 429-438.
04-01: AZURE Coleman, R. E., H. Marshall, D. Cameron, D. Dodwell, R. Burkinshaw, M. Keane, M. Gil, S. J. Houston, R. J. Grieve, P. J. Barrett-Lee, D. Ritchie, J. Pugh, C. Gaunt, U. Rea, J. Peterson, C. Davies, V. Hiley, W. Gregory, R. Bell and A. Investigators (2011). “Breast-cancer adjuvant therapy with zoledronic acid.” N Engl J Med 365(15): 1396-1405.
97-01: Prostate D’Amico, A. V., M. H. Chen, J. Crook, J. G. Armstrong, S. Malone, A. Steigler, M. Dunne, P. W. Kantoff and J. W. Denham (2011). “Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer.” J Clin Oncol 29(35): 4682-4687.
01-04: BCIRG 005 Eiermann, W., T. Pienkowski, J. Crown, S. Sadeghi, M. Martin, A. Chan, M. Saleh, S. Sehdev, L. Provencher, V. Semiglazov, M. Press, G. Sauter, M. A. Lindsay, A. Riva, M. Buyse, P. Drevot, H. Taupin and J. R. Mackey (2011). “Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.” J Clin Oncol 29(29): 3877-3884.
97-01: Prostate Fleming, C., C. Kelly, P. Thirion, K. Fitzpatrick and J. Armstrong (2011). “A method for the prediction of late organ-at-risk toxicity after radiotherapy of the prostate using equivalent uniform dose.” Int J Radiat Oncol Biol Phys 80(2): 608-613.
06-06: CIRG TORI 010 Martin, M., H. Roche, T. Pinter, J. Crown, M. J. Kennedy, L. Provencher, F. Priou, W. Eiermann, E. Adrover, I. Lang, M. Ramos, J. Latreille, A. Jagiello-Gruszfeld, T. Pienkowski, E. Alba, R. Snyder, S. Almel, J. Rolski, M. Munoz, R. Moroose, S. Hurvitz, A. Banos, H. Adewoye, Y. J. Hei, M. A. Lindsay, M. Rupin, D. Cabaribere, Y. Lemmerick, J. R. Mackey and T. investigators (2011). “Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.” Lancet Oncol 12(4): 369-376.
01-03: BCIRG 006 Slamon, D., W. Eiermann, N. Robert, T. Pienkowski, M. Martin, M. Press, J. Mackey, J. Glaspy, A. Chan, M. Pawlicki, T. Pinter, V. Valero, M. C. Liu, G. Sauter, G. von Minckwitz, F. Visco, V. Bee, M. Buyse, B. Bendahmane, I. Tabah-Fisch, M. A. Lindsay, A. Riva, J. Crown and G. Breast Cancer International Research (2011). “Adjuvant trastuzumab in HER2-positive breast cancer.” N Engl J Med 365(14): 1273-1283.
01-09: BCIRG 007 Valero, V., J. Forbes, M. D. Pegram, T. Pienkowski, W. Eiermann, G. von Minckwitz, H. Roche, M. Martin, J. Crown, J. R. Mackey, P. Fumoleau, J. Rolski, Z. Mrsic-Krmpotic, A. Jagiello-Gruszfeld, A. Riva, M. Buyse, H. Taupin, G. Sauter, M. F. Press and D. J. Slamon (2011). “Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.” J Clin Oncol 29(2): 149-156.
Study Number: Short Name

2010 Journal Publications

99-09: 3DCRT Lung Brennan, S. M., P. Thirion, S. Buckney, C. O. Shea and J. Armstrong (2010). “Factors influencing conformity index in radiotherapy for non-small cell lung cancer.” Med Dosim 35(1): 38-42.
04-01: AZURE Coleman, R. E., M. C. Winter, D. Cameron, R. Bell, D. Dodwell, M. M. Keane, M. Gil, D. Ritchie, J. L. Passos-Coelho, D. Wheatley, R. Burkinshaw, S. J. Marshall, H. Thorpe and A. Investigators (2010). “The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer.” Br J Cancer 102(7): 1099-1105.
97-02: ACCOG-1 Mansi, J. L., A. Yellowlees, J. Lipscombe, H. M. Earl, D. A. Cameron, R. E. Coleman, T. Perren, C. J. Gallagher, M. Quigley, J. Crown, A. L. Jones, M. Highley, R. C. Leonard and T. R. Evans (2010). “Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group study.” Breast Cancer Res Treat 122(3): 787-794.
Study Number: Short Name

2009 Journal Publications

05-02: NSABP C08 Allegra, C. J., G. Yothers, M. J. O’Connell, S. Sharif, L. H. Colangelo, S. H. Lopa, N. J. Petrelli, R. M. Goldberg, J. N. Atkins, T. E. Seay, L. Fehrenbacher, S. O’Reilly, L. Chu, C. A. Azar and N. Wolmark (2009). “Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.” J Clin Oncol 27(20): 3385-3390.
04-09: EGF30008 Johnston, S., J. Pippen, Jr., X. Pivot, M. Lichinitser, S. Sadeghi, V. Dieras, H. L. Gomez, G. Romieu, A. Manikhas, M. J. Kennedy, M. F. Press, J. Maltzman, A. Florance, L. O’Rourke, C. Oliva, S. Stein and M. Pegram (2009). “Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.” J Clin Oncol 27(33): 5538-5546.
Study Number: Short Name

2008 Journal Publications

04-08: EGF100151 Cameron, D., M. Casey, M. Press, D. Lindquist, T. Pienkowski, C. G. Romieu, S. Chan, A. Jagiello-Gruszfeld, B. Kaufman, J. Crown, A. Chan, M. Campone, P. Viens, N. Davidson, V. Gorbounova, J. I. Raats, D. Skarlos, B. Newstat, D. Roychowdhury, P. Paoletti, C. Oliva, S. Rubin, S. Stein and C. E. Geyer (2008). “A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.” Breast Cancer Res Treat 112(3): 533-543.
98-01: BIG 2-98 Francis, P., J. Crown, A. Di Leo, M. Buyse, A. Balil, M. Andersson, B. Nordenskjold, I. Lang, R. Jakesz, D. Vorobiof, J. Gutierrez, G. van Hazel, S. Dolci, S. Jamin, B. Bendahmane, R. D. Gelber, A. Goldhirsch, M. Castiglione-Gertsch, M. Piccart-Gebhart and B. I. G. C. Group (2008). “Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.” J Natl Cancer Inst 100(2): 121-133.
98-01: BIG 2-98 Pestalozzi, B. C., P. Francis, E. Quinaux, S. Dolci, E. Azambuja, R. D. Gelber, G. Viale, A. Balil, M. Andersson, B. Nordenskjold, M. Gnant, J. Gutierrez, I. Lang, J. P. Crown, M. Piccart-Gebhart and B. I. G. C. Group (2008). “Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial.” Ann Oncol 19(11): 1837-1841.
Study Number: Short Name

2007 Journal Publications

06-03: Epi Sulindac O’Connor, R., M. O’Leary, J. Ballot, C. D. Collins, P. Kinsella, D. E. Mager, R. D. Arnold, L. O’Driscoll, A. Larkin, S. Kennedy, D. Fennelly, M. Clynes and J. Crown (2007). “A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.” Cancer Chemother Pharmacol 59(1): 79-87.
Study Number: Short Name

2006 Journal Publications

00-01: Epilymph Besson, H., P. Brennan, N. Becker, A. Nieters, S. De Sanjose, R. Font, M. Maynadie, L. Foretova, P. L. Cocco, A. Staines, M. Vornanen and P. Boffetta (2006). “Tobacco smoking, alcohol drinking and non-Hodgkin’s lymphoma: A European multicenter case-control study (Epilymph).” Int J Cancer 119(4): 901-908.
04-08: EGF100151 Geyer, C. E., J. Forster, D. Lindquist, S. Chan, C. G. Romieu, T. Pienkowski, A. Jagiello-Gruszfeld, J. Crown, A. Chan, B. Kaufman, D. Skarlos, M. Campone, N. Davidson, M. Berger, C. Oliva, S. D. Rubin, S. Stein and D. Cameron (2006). “Lapatinib plus capecitabine for HER2-positive advanced breast cancer.” N Engl J Med 355(26): 2733-2743.
Study Number: Short Name

2004 Journal Publications

97-02: ACCOG-1 Leonard, R. C., M. Lind, C. Twelves, R. Coleman, S. van Belle, C. Wilson, J. Ledermann, I. Kennedy, P. Barrett-Lee, T. Perren, M. Verrill, D. Cameron, E. Foster, A. Yellowlees, J. Crown and G. Anglo-Celtic Cooperative Oncology (2004). “Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.” J Natl Cancer Inst 96(14): 1076-1083.
Study Number: Short Name

2002 Journal Publications

97-02: ACCOG-1 Cameron, D. A., A. Anderson, E. Toy, T. R. Evans, J. H. Le Vay, I. C. Kennedy, R. J. Grieve, T. J. Perren, A. Jones, J. Mansi, J. Crown and R. C. Leonard (2002). “Block sequential adriamycin CMF–optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?” Br J Cancer 87(12): 1365-1369.